This article first appeared on GuruFocus .
BioNTech ( NASDAQ:BNTX ), the mRNA vaccine and oncology developer, pulled the plug on its Phase 2 colorectal-cancer trial Friday, with the stock priced at $103.39. Independent monitors recommended stopping treatment with autogene cevumeran, the personalized cancer vaccine being developed alongside Roche's Genentech.
The study enrolled high-risk Stage II and Stage III patients who had undergone surgery but still carried circulating tumor DNA. It crossed a futility boundary in October 2025, but the evidence was too young to deliver a verdict. The latest review removed that uncertainty: an overall-survival imbalance emerged, and additional treatment was unlikely to reverse the efficacy outcome. BioNTech reported no new safety signal.
The valuation picture now looks demanding. At $103.39, BioNTech trades 25.79% above its GF Value estimate of $82.19, leaving investors with less room for clinical disappointment. The pancreatic-cancer program remains alive, so this is not the death of personalized mRNA vaccines. But the easy platform story just took a hard hit: success in one tumor cannot be copied and pasted into another.
